Company: SION
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001193125-25-018825
Chunk: 272

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-03
Form: S-1/A
Chunk 272
---
 by the board of directors or the compensation committee, as
applicable, and communicated to each executive. The corporate performance goals will be measured at the end of each performance period at such time as the board of directors or the compensation committee determines. If the corporate performance
goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but not later than 2.5 months after the end of the calendar year in which such performance period ends.
Subject to the rights contained in any agreement between the executive officer and us, an executive officer shall be required to be employed by us on the bonus payment date to be eligible to receive a bonus payment under the Bonus Plan. The Bonus
Plan also permits the board of directors or the compensation committee to approve additional bonuses to executive officers in its sole discretion.

Equity Grants to Employees (Including NEOs)

In connection with this offering, our board of directors approved grants to certain employees of the
Company (including our NEOs) of options to purchase an aggregate of 1,758,504 shares of common stock (the “Employee IPO Grants”) under the 2025 Plan, with Mr. Cloonan, Ms. Ridloff and Dr. McKee being granted options to purchase 450,252,
157,820 and 148,536 shares of our common stock, respectively. The Employee IPO Grants are contingent and subject to the effectiveness of the registration statement of which this prospectus forms a part, which must occur no later than February 15,
2025, after which date these Employee IPO Grants shall be forfeited. The Employee IPO Grants will each have an exercise price per share equal to the per share “price to the public” (or equivalent) set forth on the cover page for the final
prospectus relating to our initial public offering, expire ten years from the date of grant and vest in 48 equal monthly installments following their applicable vesting start date, in each case subject to the applicable employee’s continued
service relationship through each such vesting date. Vesting of the Employee IPO Grants for our NEOs will commence on the date that the registration statement of which this prospectus forms a part becomes effective. Certain of our non-employee
directors will also receive equity grants in connection with this offering, as described in more detail below under “Non-Employee Director Compensation Policy.”

194

DIRECTOR COMPENSATION The following table presents the compensation awarded to, earned by, or paid to each person who